0HTC Stock Chart & Stats
$3.38
$0.00(0.00%)
At close: 4:00 PM EDT
$3.38
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.38 - $15.99
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$17.07M
Enterprise Value$2.20
Total Cash (Recent Filing)$15.77M
Total Debt (Recent Filing)$145.00K
Price to Earnings (P/E)―
Beta-0.72
Next Earnings
Nov 12, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)-2.79
Shares Outstanding13,338,943
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.14Price Target Upside170.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 1 Target Engagement And Improved TolerabilityThe Phase 1 results provide clinical evidence that TTI-109 reaches and modulates its intended STAT3 pathway while improving tolerability versus the prior compound. This combination can support progression into later-stage studies and strengthen the candidate’s differentiation if benefits translate into patients.
Oral STAT3 Platform With Expanded Immunology FocusSelecting ulcerative colitis gives Tvardi a defined development path in a sizable area with unmet need and positions its oral, tissue-targeted STAT3 approach against therapies that address narrower pathways. A focused indication strategy may improve development coherence and platform relevance.
Low Current Debt BurdenMinimal current debt reduces interest obligations and near-term refinancing pressure, preserving more flexibility for clinical development spending. Although assets have declined and historical equity was unstable, the present capital structure is not burdened by material leverage that would directly constrain operations.
Bears Say
No Current Revenue And Persistent LossesThe absence of revenue means Tvardi currently lacks an operating income stream to fund research, administration, or future commercialization. Persistent negative EBIT and net income leave results dependent on successful clinical progress and financing, making the fundamental earnings profile weak over the coming quarters.
Sustained Cash Burn Requires External FundingOngoing cash outflows require Tvardi to secure additional capital before its pipeline can generate commercial revenue. This dependence can limit development choices, increase execution pressure around financing milestones, and make continuity of clinical programs vulnerable if funding conditions or investor support weaken.
Equity Issuance Creates Dilution And Funding DependenceThe expanded at-the-market facility provides financing access but also establishes a recurring source of potential shareholder dilution while the company remains pre-revenue. Continued reliance on equity issuance can complicate capital planning and underscores that advancement of the pipeline is not yet self-funded.
Tvardi Therapeutics News
0HTC FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest share price was $3.38 and its highest was $15.99 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $17.07M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 43 days.
How were Tvardi Therapeutics’s earnings last quarter?
Tvardi Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.704 by $0.014.
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.2%. See more information on Tvardi Therapeutics dividends here
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.55.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 13,338,943 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Tvardi Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.704. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in GB:0HTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
0HTC Stock 12 Month Forecast
Average Price Target
$9.14
▲(170.50% Upside)
Technical Analysis
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―